Drugs / Sotrovimab
Sotrovimab
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed COVID-19 2 milestones | |||||
| Filed | US (FDA) | — | COVID-19 | — | “An Emergency Use Authorization (EUA) application for sotrovimab has been submitted to the US Food and Drug Administration (FDA).” vir.bio ↗ |
| Filed | EU (EMA) | Xevudy | COVID-19 | — | “GSK and Vir also recently submitted the Marketing Authorization Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab)” vir.bio ↗ “GSK and Vir also recently submitted the Marketing Authorisation Application (MAA) to the European Medicines Agency for Xevudy (sotrovimab)” gsk.com ↗ “GSK and Vir also recently submitted the Marketing Authorization Application to the European Medicines Agency for Xevudy” vir.bio ↗ “GSK and Vir also recently submitted the Marketing Authorisation Application to the European Medicines Agency for Xevudy” gsk.com ↗ “GSK and Vir also recently submitted the Marketing Authorization Application to the European Medicines Agency for Xevudy” vir.bio ↗ |
| Approved Indication not stated 1 milestone | |||||
| Approved | EU (EMA) | Xevudy | — | 2026-02-18 | europa.eu ↗ |
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05280717 | Mar 2022 → Apr 2023 | COVID-19 | Vir Biotechnology, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05135650 | Jan → Oct 2022 | COVID-19, cancer, hematopoietic and lymphoid cell neoplasm | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT04988152 | Jul → Sep 2021 | COVID-19 | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05210101 | Feb 2022 → Feb 2023 | COVID-19 | Sophia Koo, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT05124210 | Dec 2021 → Jun 2023 | COVID-19 | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT05041907 | Sep 2021 → Jan 2027 expected | COVID-19 | University of Oxford | Recruiting | Mixed |
| Phase 2 | NCT04634409 | Oct 2020 → Jul 2021 | COVID-19 | Eli Lilly and Company | Completed | Mixed |
| Phase 2/32 trials · 1 met primary · 1 missed | ||||||
| Phase 2/3 | NCT04870333 | Feb 2021 → Apr 2025 | COVID-19 | Cambridge University Hospitals NHS Foundation Trust | Completed | Missed primary |
| Phase 2/3 | NCT04545060 | Aug 2020 → Apr 2021 | COVID-19 | Vir Biotechnology, Inc. | Completed | Met primary |
| Phase 34 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT05205759 | Dec 2021 → Feb 2022 | COVID-19 | Azienda Ospedaliera Universitaria Integrata Verona | Terminated | No outcome recorded |
| Phase 3 | NCT04913675 | Jun 2021 → Jul 2022 | COVID-19 | Vir Biotechnology, Inc. | Terminated | Met primary |
| Phase 3 | NCT05780281 | Dec 2020 → Jun 2021 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04501978 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 42 trials · 1 missed | ||||||
| Phase 4 | NCT04790786 | Mar 2021 → Jun 2022 | COVID-19 | Erin McCreary | Terminated | Missed primary |
| Phase 4 | NCT04748588 | Feb 2021 → Jan 2022 | COVID-19, nosocomial infection | University of Calgary | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05235347 | — | COVID-19 | Vir Biotechnology, Inc. | No longer available | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT04746183 Comparator | Jul 2020 → Mar 2027 expected | COVID-19 | University of Liverpool | Recruiting | Missed primary |
| Phase 2 | NCT04779879 Comparator | Feb → Aug 2021 | COVID-19 | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05271929 Background | Apr 2022 → Jan 2024 | COVID-19 | German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen | Terminated | Met primary Stop: Enrollment |
| Phase 3 | NCT05321394 Comparator | Mar 2022 → Oct 2023 | COVID-19 | Azienda Ospedaliera Universitaria Integrata Verona | Completed | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 4 | NCT05305651 Background | Jul 2022 → Jul 2023 | COVID-19 | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 41
| Date | Issuer | Release |
|---|---|---|
| 2023-02-22 | Vir Biotechnology, Inc. | Regulatory Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE) vir.bio ↗ |
| 2022-03-25 | Vir Biotechnology, Inc. | Regulatory US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant vir.bio ↗
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody. |
| 2022-02-10 | Vir Biotechnology, Inc. | Results Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2 vir.bio ↗
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that preclinical data suggest that sotrovimab, an investigational monoclonal antibody authorized for emergency use in the United States and developed in conjunction with GlaxoSmithKline, retains neutralizing activity against the BA.2 subvariant of Omicron. |
| 2022-01-13 | Vir Biotechnology, Inc. | Regulatory GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19 vir.bio ↗ |
| 2021-12-31 | Vir Biotechnology, Inc. | Results Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement vir.bio ↗
Further, these data add to the growing body of evidence from recent pseudo- and live virus neutralization findings1,2 demonstrating that sotrovimab retains activity against the Omicron variant, as well as all tested variants of concern3. |
| 2021-12-17 | GlaxoSmithKline | Regulatory Xevudy (sotrovimab) granted marketing authorisation by the European Commission for the early treatment of COVID-19 gsk.com ↗
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Commission (EC) has granted marketing authorisation to Xevudy (sotrovimab) for the early treatment of COVID-19. |
| 2021-12-17 | Vir Biotechnology, Inc. | Regulatory Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19 vir.bio ↗
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Commission (EC) has granted marketing authorization to Xevudy (sotrovimab) for the early treatment of COVID-19. |
| 2021-12-14 | Vir Biotechnology, Inc. | Results Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies vir.bio ↗
Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline, retained their in vitro neutralizing activity against Omicron. |
| 2021-12-07 | GlaxoSmithKline | Results Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant gsk.com ↗ |
| 2021-12-07 | Vir Biotechnology, Inc. | Results Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant vir.bio ↗
Vir Biotechnology, Inc. (Nasdaq: VIR) announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new data that demonstrates sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant. |
| 2021-12-07 | Vir Biotechnology, Inc. | Results Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant vir.bio ↗
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update to preclinical data on bioRxiv1, a preprint server, demonstrating that sotrovimab, an investigational monoclonal antibody, retains in vitro activity against the full known Omicron spike protein, the new SARS-CoV-2 variant (B.1.1.529). |
| 2021-12-02 | GlaxoSmithKline | Results Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant gsk.com ↗ |
| 2021-12-02 | GlaxoSmithKline | Regulatory MHRA grants conditional marketing authorisation1 for COVID-19 treatment Xevudy (sotrovimab) gsk.com ↗
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for Xevudy (sotrovimab) for the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection. |
| 2021-12-02 | Vir Biotechnology, Inc. | Results Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant vir.bio ↗ |
| 2021-11-12 | GlaxoSmithKline | Results Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19 gsk.com ↗
COMET-TAIL Phase III data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations |
| 2021-11-12 | Vir Biotechnology, Inc. | Results Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19 vir.bio ↗
In the IM administration (500mg) arm of the trial, there was a 2.7% rate of progression to hospitalization for more than 24 hours or death through Day 29 of the trial, compared to 1.3% in the IV administration arm (also 500mg). |
| 2021-08-23 | Vir Biotechnology, Inc. | Regulatory Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia vir.bio ↗
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK). |
| 2021-06-21 | GlaxoSmithKline | Results GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab gsk.com ↗
Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalisation and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease |
| 2021-06-21 | Vir Biotechnology, Inc. | Results GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab vir.bio ↗
Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease |
| 2021-05-26 | GlaxoSmithKline | Regulatory GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients gsk.com ↗
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for sotrovimab (previously VIR-7831), an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in adults and paediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalisation or death. |
| 2021-05-26 | Xencor, Inc. | Regulatory Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19 xencor.com ↗
Vir Biotechnology and GlaxoSmithKline's investigational SARS-CoV-2 antibody, engineered with the Xencor XmAb ® Fc technology, Xtend™, is authorized for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients |
| 2021-05-26 | Vir Biotechnology, Inc. | Regulatory GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients vir.bio ↗
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for sotrovimab (previously VIR-7831), an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. |
| 2021-05-21 | GlaxoSmithKline | Regulatory EMA issues positive scientific opinion on GSK and Vir Biotechnology’s sotrovimab for the early treatment of COVID-19 gsk.com ↗
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. |
| 2021-05-21 | Vir Biotechnology, Inc. | Regulatory CORRECTION -- EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19 vir.bio ↗
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. |
| 2021-05-07 | GlaxoSmithKline | Regulatory GSK and Vir Biotechnology announce the start of the EMA rolling review of VIR-7831 (sotrovimab) for the early treatment of COVID-19 gsk.com ↗ |
| 2021-05-07 | Vir Biotechnology, Inc. | Regulatory GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19 vir.bio ↗ |
| 2021-04-15 | GlaxoSmithKline | Regulatory GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19 gsk.com ↗
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19. |
| 2021-04-15 | Vir Biotechnology, Inc. | Regulatory GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19 vir.bio ↗ |
| 2021-04-08 | Vir Biotechnology, Inc. | Results Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells vir.bio ↗
The research highlights the distinct mechanism of action of non-receptor-binding motif (RBM)-targeting antibodies, such as VIR-7831 and VIR-7832, the Company’s investigational SARS-CoV-2 mAbs that target a conserved non-RBM site within the receptor binding domain (RBD). |
| 2021-04-05 | Vir Biotechnology, Inc. | Results Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant vir.bio ↗
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical research demonstrating the ability of VIR-7831, the company’s investigational SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) monoclonal antibody (mAb), to maintain its neutralizing activity against a mutation in the receptor binding domain (RBD) of SARS-CoV-2, called L452R, which is found in the California variant (B.1.427/B.1.429). |
| 2021-03-29 | GlaxoSmithKline | Results Lilly, Vir Biotechnology and GSK announce positive topline data from the phase 2 BLAZE-4 trial evaluating bamlanivimab with VIR-7831 in low-risk adults with COVID-19 gsk.com ↗
In combination, the two monoclonal antibodies demonstrated a 70% relative reduction in persistently high viral load at day 7 compared to placebo. |
| 2021-03-29 | Vir Biotechnology, Inc. | Results Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 vir.bio ↗
In combination, the two monoclonal antibodies demonstrated a 70% relative reduction in persistently high viral load at day 7 compared to placebo |
| 2021-03-29 | Eli Lilly and Company | Results Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19 lilly.com ↗
In addition, bamlanivimab administered with VIR-7831 demonstrated a statistically significant reduction compared to placebo in the key virologic secondary endpoints of mean change from baseline to days 3, 5 and 7 in SARS-CoV-2 viral load. |
| 2021-03-26 | GlaxoSmithKline | Regulatory GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19 gsk.com ↗ |
| 2021-03-26 | Vir Biotechnology, Inc. | Regulatory GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19 vir.bio ↗
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with mild-to-moderate COVID-19 who are at risk for progression to hospitalization or death. |
| 2021-03-10 | GlaxoSmithKline | Results Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19 gsk.com ↗ |
| 2021-03-10 | Vir Biotechnology, Inc. | Results Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19 vir.bio ↗
Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death |
| 2021-03-03 | GlaxoSmithKline | Results Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19 gsk.com ↗
The independent Data and Safety Monitoring Board (DSMB) has recommended that the VIR-7831 arm of the trial be closed to enrolment while the data mature. |
| 2021-03-03 | Vir Biotechnology, Inc. | Results Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 vir.bio ↗
The independent Data and Safety Monitoring Board (DSMB) has recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature. |
| 2021-02-01 | Vir Biotechnology, Inc. | Results Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics vir.bio ↗
When tested across four clinical-stage antibodies – S309 (the precursor of VIR-7831), LY-CoV555, REGN10933 and REGN10987 – S309, which targets a non-RBM epitope, LY-CoV555 and REGN10933 were capable of neutralizing the N439K variant. |
| 2020-11-06 | Vir Biotechnology, Inc. | Results Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K vir.bio ↗
When tested across four clinical-stage antibodies – S309 (the precursor of VIR-7831), LY-CoV555, REGN10933 and REGN10987 – S309, which targets a non-RBM epitope, LY-CoV555 and REGN10933 were capable of neutralizing the N439K variant. |
All press releases naming this drug 55 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sotrovimab | “Casirivimab/imdesimab 1200mg/1200mg OR sotrovimab 500mg OR bamlanivimab 700mg IV x1.” NCT04748588 ↗ |
| Known as | GSK4182136 | “Sotrovimab, VIR-7831, GSK4182136 Sterile solution for intravenous infusion, 62.5 mg/mL, intravenous infusion” NCT04870333 ↗ |
| Known as | SOT | “500 mg of intravenous sotrovimab (SOT)” PMID 39343244 ↗ Sep 2024 |
| Known as | VIR-7831 | “This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2...” NCT04779879 ↗6“Sotrovimab, VIR-7831, GSK4182136 Sterile solution for intravenous infusion, 62.5 mg/mL, intravenous infusion” NCT04870333 ↗ “VIR-7831 (sotrovimab) given by intravenous infusion (single dose)” NCT04545060 ↗ |
| Known as | Xevudy | “Sotrovimab (Xevudy)” NCT05271929 ↗ |
| Action | Inhibit | “neutralising monoclonal antibody” PMID 40886716 ↗ Aug 2025 |
| Modality | Monoclonal antibody | “neutralising monoclonal antibody” PMID 40886716 ↗ Aug 2025 |
| Route | Intravenous | “by intravenous infusion” NCT04381936 ↗ |